不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>行业动态>Kazia与肿瘤临床试验联盟达成转移性脑肿瘤临床合作

Kazia与肿瘤临床试验联盟达成转移性脑肿瘤临床合作

美通社2019年5月21日 3:55 点击:180

Kazia Therapeutics 宣布与美国癌症研究网络肿瘤临床试验联盟达成了合作。该联盟将推出多中心II期研究,调查 Kazia 研究用新药 GDC-0084 以及其他几种靶向型癌症疗法在治疗转移性脑肿瘤(已经扩散到大脑的肿瘤)方面的潜在效用。

XINI2019NIAN5YUE21RI /MEITONGSHE/ -- ZHUANZHUYUZHONGLIUZHILIAODEAODALIYASHENGWUKEJIGONGSI Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) XINRANXUANBU,GAIGONGSIYUMEIGUOGUOJIAAIZHENGYANJIUSUO (National Cancer Institute) ZANZHUDEMEIGUOAIZHENGYANJIUWANGLUOZHONGLIULINCHUANGSHIYANLIANMENG(Alliance for Clinical Trials in Oncology Foundation,JIANCHENG“GAILIANMENG”)DACHENGLEHEZUO。GAILIANMENGJIANGTUICHUDUOZHONGXINIIQIYANJIU,DIAOCHA Kazia YANJIUYONGXINYAO GDC-0084 YIJIQITAJIZHONGBAXIANGXINGAIZHENGLIAOFAZAIZHILIAOZHUANYIXINGNAOZHONGLIU(YIJINGKUOSANDAODANAODEZHONGLIU)FANGMIANDEQIANZAIXIAOYONG。


研究首席调查员、哈佛医学院 (Harvard Medical School) 医学助理教授 Priscilla Brastianos(医学博士)表示:“转移性脑肿瘤确实代表了未得到满足的临床需求。我们迫切需要为这些患者找到更好的治疗方案。我们希望这项研究能帮助我们找到一种新的治疗模式。”Brastianos 博士还是麻省总医院 (Massachusetts General Hospital) 血液学/肿瘤科的医学助理医师。她的研究重点是转移性脑肿瘤,并受到该领域刊物的广泛报道。美国各地领先中心的杰出医师专家组成的研究指导委员会将和 Brastianos 博士一起完成这项研究。

要点

  • 不用本金就能赚钱的方法GAILIANMENGJIANGZHENDUIZHUANYIXINGNAOZHONGLIUHUANZHEQIDONGKAIFANGBIAOQIANIIQIYANJIU。

  • GENJUZHONGLIUDEJIYINTEZHENG,HUANZHEJIANGBEIFENPEISHIYONG abemaciclib(LILAIGONGSI (Eli Lilly))、entrectinib(JIYINTAIKEGONGSI (Genentech))HUO GDC-0084 (Kazia Therapeutics)JIESHOUZHILIAO。

  • 不用本金就能赚钱的方法ZHEIXIANGSHIYANYUJIJIANGZAIMEIGUODUOJIAZHONGXINZHAOMUDUODA150MINGHUANZHE。

  • ZHEIXIANGSHIYANJIANGYOUGAILIANMENGFUZE,Kazia TIGONGYANJIUYAOWUHECAIZHENGZIZHUDENGZHICHI。

  • 不用本金就能赚钱的方法ZHEIXIANGYANJIUDEQIDONGYIWEIZHEZHENGZAISHIYONG GDC-0084 KAIZHANDELINCHUANGSHIYANZONGSHUDADAOSIGE,MEIGEDOUSHIBUTONGXINGSHIDENAOZHONGLIU。

DUODA30%DEZHUANYIXINGZHONGLIUHUANZHEHUIFAZHANWEINAONEIJIFAXINGZHONGLIU(ZHUANYIXINGZHONGLIU)。JINMEIGUOYIGEGUOJIA,MEINIANGUJIJIUYUEYOU20WANLIZHUANYIXINGNAOZHONGLIU。ZHILIAOFANGANRENGRANYOUXIAN,ERQIEZHUANYIXINGNAOZHONGLIUHUANZHEDEPINGJUNSHENGCUNQIWEI3ZHI27GEYUE,JUTIHAIQUJUEYUYUANFAZHONGLIUDEWEIZHIDENGYINSU。

不用本金就能赚钱的方法RENMENRIYIRENSHIDAOAIZHENGSHIYIZHONGFUZADEJIBING,LEISIBUWEI(RURUFANG、FEIDENG)DEZHONGLIUDUIZHILIAODEFANYINGKENENGYOUHENDADEBUTONG,QIZHONGYIGEZHONGYAOYINSUBIANSHIZHONGLIUDEJIYINTEZHENG。LINCHUANGYANJIUYIKAISHIBAZHONGDIANFANGZAIGENJUJIYINTEZHENGZIXIFENPEIBINGRENJINXINGZHILIAOSHANG,ZHEIZHONGFANGFAYOUSHIBEICHENGWEI“JINGZHUNYILIAO”HUO“GEXINGHUAYILIAO”。GAILIANMENGDEYANJIUBIANSHIZHEIZHONGFANGFADEYIGELIZI。

GAILIANMENGDEYANJIUYOUCHENG“A071701”,YUJIJIANGYIGONGZHAOMUDUODA150MINGHUANZHE,SUOYOUZHEIXIEHUANZHEDEZHONGLIUDOUYIJINGKUOSANDAOLEDANAO。ZHIYOU PI3K TONGLUFASHENGJIYINGAIBIANDEHUANZHEHUIJIESHOU GDC-0084 ZHILIAO。SUOYOUZHAOMUDEHUANZHEZHONG,YUJIJIANGYUEYOU1/3BEIFENPEIDAOZHEIYIZU。QITAJIYINTUBIANHUANZHEJIANGBEIFENPEIJIESHOU CDK YIZHIJI abemaciclib(YOUMING Verzenio™,LILAIGONGSISHENGCHAN,YIHUOMEIGUOSHIPINHEYAOWUGUANLIJU (FDA) PIZHUNYONGYUZHILIAOMOUXIEXINGSHIDERUXIANAI)HUO Trk/ALK YIZHIJI entrectinib(JIYINTAIKEGONGSISHENGCHAN,SHANGWEIHUO FDA PIZHUN)。

Kazia Therapeutics 首席执行官詹姆斯-加纳 (James Garner) 博士评论道:“该联盟的研究是一项突破性研究项目,目标通过一项临床研究调查几种试验药物。研究将根据患者肿瘤的基因特征对他们进行分配治疗。有影响 PI3K 通路的突变的患者将接受 GDC-0084 治疗。这种方法在很大程度上代表着癌症治疗的未来。GDC-0084 能被选中,我们感到很高兴。我们也很高兴看到这项研究取得进展。”

CICIYANJIUDEQIDONGYIWEIZHEZHENGZAISHIYONGGDC-0084KAIZHANDELINCHUANGSHIYANZONGSHUDADAOSIGE:

赞助商

阶段

适应症

注册

Kazia Therapeutics

II期

成胶质细胞瘤

NCT03522298

丹娜法伯癌症研究院(Dana-Farber Cancer Institute)

II期

乳腺癌转移性脑肿瘤

使用Herceptin®

NCT03765983

肿瘤临床试验联盟

II期

转移性脑肿瘤

(待公布)

St Jude Children's Research Hospital(圣犹达儿童研究医院)

I期

DIPG(儿童脑肿瘤)

NCT03696355

JUYUJI,ZHEIXIANGYANJIUDAYUEXUYAOLIANGNIANSHIJIANCAINENGWANCHENG。Kazia JIANGTIGONGZHICHI,BAOKUOYONGYUZHIFUBUFENFEIYONGDECAIZHENGZIZHU。ZHEIXIANGYANJIUJIANGGENJUMEIGUO FDA DE“YANJIUXINGIND”KAIZHAN,YANJIUDEZHUYAOJIANGUANZERENJIANGYOUGAILIANMENGCHENGDAN。ZHEIXIANGYANJIUDEZHIXINGQUJUEYUSHIYONGJIGOUSHENCHAWEIYUANHUIDEPIZHUNHEHETONGSHOUXUDEWANCHENG,ZHEIXIESHIXIANGSHANGWEIZUIZHONGQUEDING。JUYUJI,ZHEIXIANGYANJIUJIANGYU2019RILINIANDUXIABANNIANKAISHIZHAOMUHUANZHE。

Kazia Therapeutics Limited简介

不用本金就能赚钱的方法Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) ZONGBUWEIYUAODALIYAXINI,SHIYIJIAZHUANZHUYUZHONGLIUZHILIAODECHUANGXINSHENGWUKEJIGONGSI。GAIGONGSIDEYANFAGUANXIANBAOHANLIANGZHONGLINCHUANGJIEDUANDEHOUXUANKAIFAYAOWU,MUQIANZHENGZAIWEIYIXILIEZHONGLIUSHIYINGZHENGKAIFALIAOFA。

GAIGONGSIDEXIANDAOXIANGMU GDC-0084 SHIYIZHONG PI3K / AKT / mTOR XINHAOTONGLUXIAOFENZIYIZHIJI,YONGYUZHILIAOZUIWEICHANGJIANHEQINXIXINGZUIQIANGDECHENGRENYUANFAXINGNAOLIU -- DUOXINGXINGCHENGJIAOZHIXIBAOLIU。Kazia ZAI2016NIANMOCONGJIYINTAIKEGONGSINEILIHUODEGUANYUGDC-0084 DEKAIFASHOUQUAN,GDC-0084ZAI2018NIANJINRUERQILINCHUANGSHIYAN。CHUBUANQUANSHUJUYU2019NIAN5YUEDUIWAIGONGBU,YOUXIAOXINGSHUJUZEYUJIJIANGYU2019NIANXIABANNIANDUIWAIGONGBU。2018NIAN2YUE,GDC-0084 HUODEMEIGUOSHIPINHEYAOWUGUANLIJUCHENGJIAOZHIXIBAOLIUGUERYAODEZIGERENDING。

TRX-E-002-1 (Cantrixil) SHIYIZHONGDISANDAIBENBINGBINANFENZI,YONGYOUDUIKANGAIZHENGGANXIBAODEHUOXING,MUQIANZHENGZAIWEIZHILIAOLUANCHAOAIJINXINGKAIFA。TRX-E-002-1 MUQIANZAIAODALIYAHEMEIGUOJINXINGYIQILINCHUANGSHIYAN。CHUBUSHUJUYIYU2019NIAN4YUEZAIMEIGUOAIZHENGYANJIUXIEHUI (AACR) NIANHUIGONGBU,XIANGGUANYANJIURENGZAIJINXING。2015NIAN4YUE,Cantrixil HUODE FDA LUANCHAOAIGUERYAODEZIGERENDING。

肿瘤临床试验联盟简介

不用本金就能赚钱的方法ZHONGLIULINCHUANGSHIYANLIANMENG(JIANCHENG“GAILIANMENG”)SHIYOUMEIGUOHEJIANADAYUE10000MINGYISHIZUCHENGDELINCHUANGSHIYANWANGLUO。GAILIANMENGLIQIUTONGGUOTUANJIEZHONGDUOXUEKEDEKEXUEJIAHELINCHUANGYISHENG,ZHILIYUFAXIAN、YANZHENGHECHUANBOYUFANGHEZHILIAOAIZHENGDEYOUXIAOZHANLVE,JIANSHAOAIZHENGDUIRENMENDEYINGXIANG。GAILIANMENGSHIMEIGUOGUOJIAAIZHENGYANJIUSUO(JIANCHENG“NCI”)ZANZHUDEGUOJIALINCHUANGSHIYANWANGLUO(National Clinical Trials Network,JIANCHENG“NCTN”)DEYIBUFEN。

TUBIAO - 

  

 

消息来源:Kazia Therapeutics Limited


(来源: 美通社


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。
湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图